Daiwa Securities Group
MRSN

Daiwa Securities Group’s Mersana Therapeutics MRSN Stock Holding History

Daiwa Securities Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$1K – 1365
2023
Q3 		$1K Hold
16
– – ﹤0.01% 1263
2023
Q2 		$1K Hold
16
– – ﹤0.01% 1285
2023
Q1 		$2K Hold
16
– – ﹤0.01% 1221
2022
Q4 		$2K Buy
16
+6
+60% +$1.01K ﹤0.01% 1230
2022
Q3 		$2K Hold
10
– – ﹤0.01% 1237
2022
Q2 		$1K Hold
10
– – ﹤0.01% 1303
2022
Q1 		$1K Hold
10
– – ﹤0.01% 1318
2021
Q4 		$2K Hold
10
– – ﹤0.01% 1288
2021
Q3 		$2K Buy
10
+5
+100% +$1.46K ﹤0.01% 1244
2021
Q2 		$2K Hold
5
– – ﹤0.01% 1144
2021
Q1 		$2K Hold
5
– – ﹤0.01% 1147
2020
Q4 		$3K Buy
+5
New +$2.78K ﹤0.01% 1091
2018
Q4 		– Sell
-5
Closed -$1K – 1166
2018
Q3 		$1K Hold
5
– – ﹤0.01% 1148
2018
Q2 		$2K Hold
5
– – ﹤0.01% 1141
2018
Q1 		$2K Buy
+5
New +$1.97K ﹤0.01% 1130

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Daiwa Securities Group's MRSN Position: Q4 2023 in Review

Daiwa Securities Group sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 16 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in MRSN in Q1 2018 and held it in 15 quarters. The position peaked at $3K in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Daiwa Securities Group reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 16 Mersana Therapeutics shares in Q4 2023, an estimated $1K.
  • Daiwa Securities Group first reported a position in Mersana Therapeutics in Q1 2018 and held it in 15 quarters.
  • Daiwa Securities Group's Mersana Therapeutics position peaked at $3K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.